Targeting TLR4 synergistically with the pyrine domain-containing receptor (NLRP3), known to be a component of the inflammasome, a multi-protein signaling complex responsible for caspase-1 activation and subsequent maturation of IL-1β and pro-IL-18, is also an effective treatment for IBD. Here, IL1B is linked to inflammatory bowel disease.